Pulmonx (LUNG) Set to Announce Quarterly Earnings on Wednesday

Pulmonx (NASDAQ:LUNG) will release its earnings data after the market closes on Wednesday, October 30th. Analysts expect Pulmonx to post earnings of ($0.43) per share for the quarter. Pulmonx has set its FY 2024 guidance at EPS.Investors that wish to listen to the company’s conference call can do so using this link.

Pulmonx (NASDAQ:LUNG) last issued its earnings results on Wednesday, July 31st. The company reported ($0.39) EPS for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.02. The business had revenue of $20.78 million during the quarter, compared to analyst estimates of $20.23 million. Pulmonx had a negative return on equity of 50.79% and a negative net margin of 75.56%. On average, analysts expect Pulmonx to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Pulmonx Trading Down 1.8 %

Shares of Pulmonx stock opened at $6.13 on Wednesday. The company’s fifty day moving average price is $7.30 and its two-hundred day moving average price is $7.35. The firm has a market capitalization of $237.94 million, a PE ratio of -3.98 and a beta of 0.64. Pulmonx has a 52-week low of $5.46 and a 52-week high of $14.84. The company has a debt-to-equity ratio of 0.37, a current ratio of 8.97 and a quick ratio of 7.92.

Analyst Ratings Changes

A number of research analysts have commented on the stock. Canaccord Genuity Group raised their price target on shares of Pulmonx from $15.00 to $16.00 and gave the stock a “buy” rating in a research note on Thursday, August 1st. Wells Fargo & Company lowered their price target on Pulmonx from $14.00 to $10.00 and set an “equal weight” rating on the stock in a research report on Thursday, August 1st. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat, Pulmonx currently has a consensus rating of “Moderate Buy” and an average target price of $14.83.

Insider Transactions at Pulmonx

In other Pulmonx news, Director Glendon E. French III sold 20,000 shares of Pulmonx stock in a transaction on Thursday, October 17th. The stock was sold at an average price of $6.52, for a total value of $130,400.00. Following the completion of the transaction, the director now owns 1,091,974 shares in the company, valued at approximately $7,119,670.48. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In related news, CEO Steven S. Williamson bought 14,245 shares of Pulmonx stock in a transaction dated Tuesday, August 20th. The shares were bought at an average cost of $6.84 per share, for a total transaction of $97,435.80. Following the completion of the transaction, the chief executive officer now owns 219,531 shares of the company’s stock, valued at approximately $1,501,592.04. This trade represents a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Glendon E. French III sold 20,000 shares of the firm’s stock in a transaction that occurred on Thursday, October 17th. The shares were sold at an average price of $6.52, for a total transaction of $130,400.00. Following the completion of the sale, the director now directly owns 1,091,974 shares of the company’s stock, valued at approximately $7,119,670.48. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 50,351 shares of company stock valued at $361,494 in the last three months. 5.70% of the stock is owned by corporate insiders.

Pulmonx Company Profile

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.